Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com started coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a research note published on Thursday. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Price Performance

The firm has a 50-day simple moving average of $15.19 and a 200-day simple moving average of $13.17. The stock has a market capitalization of $24.33 million, a P/E ratio of -0.25 and a beta of 0.41. Cara Therapeutics has a fifty-two week low of $8.13 and a fifty-two week high of $31.32.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the stock. Rockefeller Capital Management L.P. acquired a new position in Cara Therapeutics during the fourth quarter valued at approximately $953,000. Shay Capital LLC acquired a new stake in shares of Cara Therapeutics in the fourth quarter worth $524,000. Finally, Curi RMB Capital LLC purchased a new position in shares of Cara Therapeutics in the 4th quarter valued at $277,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

Cara Therapeutics Company Profile

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.